Mandate

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.

Calliditas Therapeutics is a biopharma company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market in the US focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The total value of the offer amounts to approximately SEK 11,164 million, based on the total number of outstanding shares in Calliditas Therapeutics. Vinge advises Calliditas Therapeutics.

Vinge’s team has mainly consisted of Dain Hård Nevonen, Linnéa Sellström, William Kåge and Benjamin Vafaeian (Capital Markets and Public M&A) and Daniel Wendelsson (FDI).

Related

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026

Vinge has advised Folksam Group in connection with two investments in infrastructure funds

Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
October 08, 2026